Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Chemours manages titanium dioxide pricing cycles, PFAS litigation reserves, or refrigerant phase-down costs can feel like wading through hundreds of pages of SEC text. Our platform tackles that complexity head-on. The moment a Chemours 8-K material events explained notice or Chemours insider trading Form 4 transactions hits EDGAR, Stock Titan’s AI parses it, flags the environmental, legal, and segment earnings details investors hunt for, and delivers a clear summary you can read in minutes.
Need the latest Chemours quarterly earnings report 10-Q filing? We link the PDF, highlight Ti-Pure™ pricing disclosures, and translate footnotes into plain English. Curious about executive moves? Real-time alerts on Chemours Form 4 insider transactions real-time show exactly when directors buy or sell—critical context before pigment price announcements. Our coverage spans every form: the annual report—Chemours annual report 10-K simplified—with AI-driven red-line comparisons, the proxy statement outlining Chemours proxy statement executive compensation, down to niche S-3 shelf registrations.
Professionals use these insights to: 1) monitor litigation accrual swings quarter-to-quarter, 2) compare segment EBITDA trends without digging through exhibits, 3) follow Chemours executive stock transactions Form 4 ahead of earnings. Whether you ask “understanding Chemours SEC documents with AI” or search “Chemours earnings report filing analysis,” this page delivers concise answers, complete filings, and expert context—all continuously updated so you never miss a disclosure that moves the stock.
The Chemours Company (CC) reporting person Will David, identified as the company's Chief Accounting Officer, reported a routine tax-withholding transaction tied to vested restricted stock units and dividend equivalent units. On 08/12/2025 2,374 shares were withheld at a price of $12.42 to satisfy tax obligations; no shares were sold and the transaction is exempt under Rule 16b-3. After the withholding, Mr. David beneficially owns 25,189.8011 shares (direct ownership). The filing includes a Power of Attorney as Exhibit 24 and was signed by an attorney-in-fact on 08/14/2025.
Denise Dignam, President & CEO and director of The Chemours Company (CC), purchased common stock on 08/08/2025. The Form 4 shows a purchase of 4,068 shares at a price of $12.06 per share, bringing her total reported beneficial ownership to 191,546.1549 shares. The filing notes the reported total includes directly owned shares, restricted stock units and dividend equivalent units.
The disclosure is a standard Section 16 insider report of a non-derivative acquisition and was submitted via Form 4. No options, conversions or derivative transactions are reported on this filing.
The Chemours Company reported an insider transaction by Shane Hostetter, its Chief Financial Officer. The filing shows 3,021 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. The report indicates these withholding transactions were exempt under Rule 16b-3 and that no shares were sold in connection with the withholding.
The filing lists a per-share price of $12 for the withheld shares and shows total beneficial ownership following the transaction of 57,115.1539 shares, which the filer states includes directly owned shares, restricted stock units and dividend equivalent units.
The Schedule 13G/A for The Chemours Company shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported aggregate beneficial ownership of 7,576,095 shares of Chemours common stock, equal to 5.1% of the class. The filing specifies shared voting power of 7,443,038 and shared dispositive power of 7,576,095, and reports sole voting and dispositive powers as 0.
The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of July 1, 2025." The amendment is signed August 7, 2025, and includes a Joint Filing Agreement as Exhibit I. No purchase prices, transaction dates, or intent to influence control are disclosed in the document.
On 08/01/2025, Chemours (CC) President & CEO Denise Dignam filed a Form 4 disclosing an automatic share withholding (Transaction Code F) tied to vested restricted stock units.
- Shares withheld: 466 common shares at $11.50, executed solely to satisfy tax obligations; no open-market sale occurred and the trade is Rule 16b-3 exempt.
- Remaining ownership: 187,478.1549 shares held directly, meaning the transaction reduced her stake by roughly 0.25%.
- Insider role: Dignam serves as both President & CEO and Director, maintaining substantial equity alignment with investors.
The event is routine, immaterial to Chemours’ capital structure and does not signal a change in insider sentiment.
Chemours Company (CC) Form 4 filing – 8/1/2025
President, Thermal & Specialized Solutions, Joseph T. Martinko reported an automatic share disposition coded “F,” indicating 649 common shares were withheld by the company at $11.50 to cover taxes triggered by the vesting of restricted stock units (RSUs) and related dividend-equivalent units. No shares were sold on the open market; therefore, the transaction is exempt under Rule 16b-3.
- Post-transaction beneficial ownership: 30,936.6241 shares (direct)
- Insider role: Executive officer – President, Thermal & Specialized Solutions
- Purpose: Tax withholding; routine administrative event
Given the small share count (<0.1% of total ownership) and non-cash nature, the filing is considered operationally routine with minimal investment impact.
FAQ
What is the current stock price of Chemours Co (CC)?
What is the market cap of Chemours Co (CC)?
